Annotated Medicine and Device Lists
| List | Section | Observation |
|---|---|---|
| Peru | 6.2.1.3 Carbapenems | No observations |
| Colombia | 5.0 Others | No observations |
| Cuba | 6.2.1 Penicilinas | No observations |
| WHO Model List of Essential Medicines (2021) | 6.2.2 Watch group antibiotics |
Age or weight restriction:
> 3 months Others observations: SECOND CHOICE − Acute bacterial meningitis in neonates [c] − Complicated intraabdominal infections (severe) − High-risk febrile neutropenia Therapeutic alternatives*: imipenem + cilastatin *complicated intraabdominal infections and high-risk febrile neutropenia only. Meropenem is the preferred choice for acute bacterial meningitis in neonates. |
| WHO Model List of Essential Medicines (2021) | 6.2.5. Antituberculosis medicines |
Others observations: Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control. Therapeutic alternatives: imipenem + cilastatin |
| List | Section | Observation |
|---|---|---|
| Colombia | 5.0 Others | No observations |
| Cuba | 6.2.1 Penicilinas | No observations |
| WHO Model List of Essential Medicines (2021) | 6.2.2 Watch group antibiotics |
Age or weight restriction:
> 3 months Others observations: SECOND CHOICE − Acute bacterial meningitis in neonates [c] − Complicated intraabdominal infections (severe) − High-risk febrile neutropenia Therapeutic alternatives*: imipenem + cilastatin *complicated intraabdominal infections and high-risk febrile neutropenia only. Meropenem is the preferred choice for acute bacterial meningitis in neonates. |
| WHO Model List of Essential Medicines (2021) | 6.2.5. Antituberculosis medicines |
Others observations: Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control. Therapeutic alternatives: imipenem + cilastatin |